Kayvan R Keshari1,2, David M Wilson3, Mark Van Criekinge3, Renuka Sriram3, Bertram L Koelsch3, Zhen J Wang3, Henry F VanBrocklin3, Donna M Peehl4, Tom O'Brien5, Deepak Sampath5, Richard A D Carano6, John Kurhanewicz3. 1. Department of Radiology, Memorial Sloan-Kettering Cancer Center (MSKCC), New York. 2. Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center (MSKCC), New York. 3. Department of Radiology and Biomedical Imaging, University of California, San Francisco, California. 4. Department of Urology, Stanford University, Stanford, California. 5. Department of Translational Oncology, Genentech Inc., South San Francisco, California. 6. Department of Biomedical Imaging, Genentech Inc., South San Francisco, California.
Abstract
BACKGROUND: Metabolic shifts in disease are of great interest for the development of novel therapeutics. In cancer treatment, these therapies exploit the metabolic phenotype associated with oncogenesis and cancer progression. One recent strategy involves the depletion of the cofactors needed to maintain the high rate of glycolysis seen with the Warburg effect. Specifically, blocking nicotinamide adenine dinucleotide (NAD) biosynthesis via nicotinamide phosphoribosyltransferase (NAMPT) inhibition depletes cancer cells of the NAD needed for glycolysis. To characterize this metabolic phenotype in vivo and describe changes in flux with treatment, non-invasive biomarkers are necessary. One such biomarker is hyperpolarized (HP) [1-(13) C] pyruvate, a clinically translatable probe that allows real-time assessment of metabolism. METHODS: We therefore developed a cell perfusion system compatible with HP magnetic resonance (MR) and positron emission tomography (PET) to develop translatable biomarkers of response to NAMPT inhibition in reduced volume cell cultures. RESULTS: Using this platform, we observed a reduction in pyruvate flux through lactate dehydrogenase with NAMPT inhibition in prostate cancer cells, and showed that both HP lactate and 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) can be used as biomarkers for treatment response of such targeted agents. Moreover, we observed dynamic flux changes whereby HP pyruvate was re-routed to alanine, providing both positive and negative indicators of treatment response. CONCLUSIONS: This study demonstrated the feasibility of a MR/PET compatible bioreactor approach to efficiently explore cell and tissue metabolism, the understanding of which is critical for developing clinically translatable biomarkers of disease states and responses to therapeutics.
BACKGROUND: Metabolic shifts in disease are of great interest for the development of novel therapeutics. In cancer treatment, these therapies exploit the metabolic phenotype associated with oncogenesis and cancer progression. One recent strategy involves the depletion of the cofactors needed to maintain the high rate of glycolysis seen with the Warburg effect. Specifically, blocking nicotinamide adenine dinucleotide (NAD) biosynthesis via nicotinamide phosphoribosyltransferase (NAMPT) inhibition depletes cancer cells of the NAD needed for glycolysis. To characterize this metabolic phenotype in vivo and describe changes in flux with treatment, non-invasive biomarkers are necessary. One such biomarker is hyperpolarized (HP) [1-(13) C] pyruvate, a clinically translatable probe that allows real-time assessment of metabolism. METHODS: We therefore developed a cell perfusion system compatible with HP magnetic resonance (MR) and positron emission tomography (PET) to develop translatable biomarkers of response to NAMPT inhibition in reduced volume cell cultures. RESULTS: Using this platform, we observed a reduction in pyruvate flux through lactate dehydrogenase with NAMPT inhibition in prostate cancer cells, and showed that both HP lactate and 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) can be used as biomarkers for treatment response of such targeted agents. Moreover, we observed dynamic flux changes whereby HP pyruvate was re-routed to alanine, providing both positive and negative indicators of treatment response. CONCLUSIONS: This study demonstrated the feasibility of a MR/PET compatible bioreactor approach to efficiently explore cell and tissue metabolism, the understanding of which is critical for developing clinically translatable biomarkers of disease states and responses to therapeutics.
Authors: Mounia Beloueche-Babari; L Elizabeth Jackson; Nada M S Al-Saffar; Suzanne A Eccles; Florence I Raynaud; Paul Workman; Martin O Leach; Sabrina M Ronen Journal: Mol Cancer Ther Date: 2006-01 Impact factor: 6.261
Authors: Ralph J DeBerardinis; Anthony Mancuso; Evgueni Daikhin; Ilana Nissim; Marc Yudkoff; Suzanne Wehrli; Craig B Thompson Journal: Proc Natl Acad Sci U S A Date: 2007-11-21 Impact factor: 11.205
Authors: Sam E Day; Mikko I Kettunen; Ferdia A Gallagher; De-En Hu; Mathilde Lerche; Jan Wolber; Klaes Golman; Jan Henrik Ardenkjaer-Larsen; Kevin M Brindle Journal: Nat Med Date: 2007-10-28 Impact factor: 53.440
Authors: Renuka Sriram; Jinny Sun; Javier Villanueva-Meyer; Christopher Mutch; Justin De Los Santos; Jason Peters; David E Korenchan; Kiel Neumann; Mark Van Criekinge; John Kurhanewicz; Oren Rosenberg; David Wilson; Michael A Ohliger Journal: ACS Infect Dis Date: 2018-02-13 Impact factor: 5.084
Authors: Kristin L Granlund; Sui-Seng Tee; Hebert A Vargas; Serge K Lyashchenko; Ed Reznik; Samson Fine; Vincent Laudone; James A Eastham; Karim A Touijer; Victor E Reuter; Mithat Gonen; Ramon E Sosa; Duane Nicholson; YanWei W Guo; Albert P Chen; James Tropp; Fraser Robb; Hedvig Hricak; Kayvan R Keshari Journal: Cell Metab Date: 2019-09-26 Impact factor: 27.287
Authors: Bradley T Scroggins; Masayuki Matsuo; Ayla O White; Keita Saito; Jeeva P Munasinghe; Carole Sourbier; Kazutoshi Yamamoto; Vivian Diaz; Yoichi Takakusagi; Kazuhiro Ichikawa; James B Mitchell; Murali C Krishna; Deborah E Citrin Journal: Clin Cancer Res Date: 2018-03-29 Impact factor: 12.531
Authors: Daniele Mammoli; Jeremy Gordon; Adam Autry; Peder E Z Larson; Yan Li; Hsin-Yu Chen; Brian Chung; Peter Shin; Mark Van Criekinge; Lucas Carvajal; James B Slater; Robert Bok; Jason Crane; Duan Xu; Susan Chang; Daniel B Vigneron Journal: IEEE Trans Med Imaging Date: 2019-07-02 Impact factor: 10.048
Authors: Graham H Read; Natsuko Miura; Jenna L Carter; Kelsey T Kines; Kazutoshi Yamamoto; Nallathamby Devasahayam; Jason Y Cheng; Kevin A Camphausen; Murali C Krishna; Aparna H Kesarwala Journal: Colloids Surf B Biointerfaces Date: 2018-06-18 Impact factor: 5.268
Authors: Hecong Qin; Vickie Zhang; Robert A Bok; Romelyn Delos Santos; J Adam Cunha; I-Chow Hsu; Justin Delos Santos Bs; Jessie E Lee; Subramaniam Sukumar; Peder E Z Larson; Daniel B Vigneron; David M Wilson; Renuka Sriram; John Kurhanewicz Journal: Int J Radiat Oncol Biol Phys Date: 2020-04-25 Impact factor: 7.038
Authors: Sui Seng Tee; Valentina DiGialleonardo; Roozbeh Eskandari; Sangmoo Jeong; Kristin L Granlund; Vesselin Miloushev; Alex J Poot; Steven Truong; Julio A Alvarez; Hannah N Aldeborgh; Kayvan R Keshari Journal: Sci Rep Date: 2016-09-06 Impact factor: 4.379
Authors: John Kurhanewicz; Daniel B Vigneron; Jan Henrik Ardenkjaer-Larsen; James A Bankson; Kevin Brindle; Charles H Cunningham; Ferdia A Gallagher; Kayvan R Keshari; Andreas Kjaer; Christoffer Laustsen; David A Mankoff; Matthew E Merritt; Sarah J Nelson; John M Pauly; Philips Lee; Sabrina Ronen; Damian J Tyler; Sunder S Rajan; Daniel M Spielman; Lawrence Wald; Xiaoliang Zhang; Craig R Malloy; Rahim Rizi Journal: Neoplasia Date: 2018-11-23 Impact factor: 5.715
Authors: Renuka Sriram; Mark Van Criekinge; Justin DeLos Santos; Kayvan R Keshari; David M Wilson; Donna Peehl; John Kurhanewicz; Zhen J Wang Journal: Tomography Date: 2016-03